Comparative Pharmacology
Head-to-head clinical analysis: ALDURAZYME versus ELELYSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDURAZYME versus ELELYSO.
ALDURAZYME vs ELELYSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
Recombinant human glucocerebrosidase; hydrolyzes glucocerebroside to glucose and ceramide, reducing accumulated glucocerebroside in lysosomes of macrophages.
0.58 mg/kg administered intravenously once weekly.
60 U/kg administered intravenously over 60 minutes every 2 weeks.
None Documented
None Documented
Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses
Mean terminal elimination half-life ranges from 6.1 to 8.9 minutes after intravenous infusion; rapid clearance due to receptor-mediated uptake.
Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination
Primarily catabolized via peptide hydrolysis; renal excretion of small peptide fragments and amino acids; less than 1% excreted unchanged in urine.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy